<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875508</url>
  </required_header>
  <id_info>
    <org_study_id>M16-005</org_study_id>
    <nct_id>NCT03875508</nct_id>
  </id_info>
  <brief_title>A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Multicenter, Single-Arm, Open Label, Assessor-Blinded Study to Assess the Usability of the Risankizumab Autoinjector Combination Product in Adult Patients With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the usability of the combination product of
      risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and
      tolerability of risankizumab administered by AI for the treatment of participants with
      moderate to severe plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">August 25, 2020</completion_date>
  <primary_completion_date type="Actual">April 24, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with an Observer rating of successful participant self-administration</measure>
    <time_frame>Up to Week 28</time_frame>
    <description>Successful participant self-administration is defined as any participants who successfully completed the sequence of 4 critical steps in the Instructions for Use (IFU) without errors to administer study drug via the AI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving Psoriasis Area Severity Index (PASI) 90</measure>
    <time_frame>At Week 16</time_frame>
    <description>PASI 90 is defined as at least 90% improvement from baseline in PASI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving static physician global assessment (sPGA) of clear or almost clear</measure>
    <time_frame>At Week 16</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving PASI 100</measure>
    <time_frame>At Week 16</time_frame>
    <description>PASI 100 is defined as 100% improvement from baseline in PASI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving PASI 75</measure>
    <time_frame>At Week 16</time_frame>
    <description>PASI 75 is defined as at least 75% improvement from baseline in PASI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who had no potential hazards</measure>
    <time_frame>Up to Week 28</time_frame>
    <description>Potential hazards are measured by an observer on the possible use-related hazards checklist for self-administration with AI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant rating of acceptability by the Self-Injection Assessment Questionnaire (SIAQ)</measure>
    <time_frame>Up to Week 28</time_frame>
    <description>SIAQ is an electronic patient-report outcome (ePRO) device used to measure acceptability of the AI.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Risankizumab autoinjector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be self-administering risankizumab using a pre-filled autoinjector</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risankizumab</intervention_name>
    <description>Risankizumab to be injected subcutaneously (SC)</description>
    <arm_group_label>Risankizumab autoinjector</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>BI 655066</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Autoinjector</intervention_name>
    <description>Single dose pre-filled autoinjector containing risankizumab for SC injection</description>
    <arm_group_label>Risankizumab autoinjector</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has diagnosis of chronic plaque psoriasis for at least 6 months before the
             baseline visit.

          -  Participant meets following disease activity criteria:

               -  Stable moderate to severe chronic plaque psoriasis, defined as greater than or
                  equal to 10% body surface area (BSA) psoriasis involvement, static physician
                  global assessment (sPGA) score of greater than or equal to 3, and Psoriasis Area
                  Severity Index (PASI) greater than or equal to 12 at Screening and baseline
                  visit.

               -  Candidate for systemic therapy as assessed by the investigator.

        Exclusion Criteria:

          -  Participant has history of active skin disease other than psoriasis that could
             interfere with the assessment of psoriasis.

          -  Participant has history of erythrodermic psoriasis, generalized or localized pustular
             psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset
             guttate psoriasis.

          -  Participant has previous exposure to risankizumab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Research Associates /ID# 210634</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials /ID# 210770</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-4446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research /ID# 211386</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913-6404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakersfield Derma &amp; Skin Cance /ID# 210773</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encino Research Center / T. Jo /ID# 211735</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tien Q Nguyen MD, Inc /ID# 210775</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708-3701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis, Dermatology /ID# 210411</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Physicians of CT /ID# 210637</name>
      <address>
        <city>Shelton</city>
        <state>Connecticut</state>
        <zip>06484-6211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Academic Centers Research /ID# 210337</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medallion Clinical Research Institute, LLC /ID# 210329</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research /ID# 210878</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epiphany Dermatology /ID# 211493</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermAssociates /ID# 210838</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group,Inc /ID# 210192</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Skin Centre /ID# 211596</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology, PC /ID# 210301</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AllCutis Research Inc /ID# 211429</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medication Management, LLC /ID# 213217</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Res Center PC /ID# 210334</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh MC /ID# 210839</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies /ID# 211565</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies /ID# 210362</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates /ID# 212210</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Center for Clinical Research /ID# 212203</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research /ID# 212209</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Mem Lutheran Hosp /ID# 210194</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Risankizumab</keyword>
  <keyword>Plaque Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

